< Back to all clusters
[BUSINESS] · United States · 10 sources

started · updated

Part of situation: (2 clusters)

Stryker reports strong Q2 2026 earnings as shares drop 9%

U.S. medical‑device maker Stryker posted robust second‑quarter 2026 results. Revenue for the quarter was $6.6 billion, topping analysts' $6.58 billion estimate, while total sales for the first half of fiscal 2026 reached $12.609 billion, a 5% constant‑currency rise. The medical‑surgery and neurotechnology segment generated $3.6 billion, up 9.7% year‑over‑year but missing the $3.72 billion forecast. The orthopedics segment posted $3.0 billion in sales, a 9.1% increase that beat the $2.72 billion expectation. Adjusted earnings per share were $3.69, exceeding the $3.49 consensus. Stryker narrowed its adjusted annual profit outlook to $14.95‑$15.10 per share. Despite the beat, the stock fell about 9% in extended trading. The MedSurg and neurotechnology segment contributed $6.832 billion, a 6.5% rise, and the company’s operating margin was reported at 26.7% in a separate European release.

Entities

Juan Carlos Botzotz · Kevin Lobo · MedSurg and Neurotechnology segment · Medical surgery and neurotechnology unit · Orthopedics segment · Stryker Corp · Stryker Corporation

Claims

What the coverage asserts, and how well corroborated each claim is across sources.